Vitamins China E-News(Vitamins China E-News 202210)

Due to the tight supply and price jumps of trimethylamine—an upstream raw material, the price of choline chloride in Oct. climbed month on month. Meanwhile, the breeding industry, a downstream industry of choline chloride, is recovering. Boosted by dual favourable factors including rising price of upstream raw material and increased demand from downstream, the price of choline chloride is expected to keep on rising in the short term.

Strategic planning for carbon dioxide peaking and carbon neutrality has been made by the Chinese authorities, which authorised the drafting of Guide for Enterprises to Draw Up Action Plans of Carbon Dioxide Peaking and unveiled numerous policies for H2 2022. The cities and provinces that recently promulgated polices pertinent to carbon dioxide peaking and carbon neutrality are the places where most of the production capacities for vitamins are located in.

Chengdu Okay Pharmaceutical Co., Ltd. plans to launch an initial public offering (IPO) on Beijing Stock Exchange. Okay Pharma specialises in the extraction of natural vitamin P from plants. Some of the funds raised in IPO will be invested in its new project, which will not only largely improve the company's production capacity, but also enrich the product bank.

North China Pharmaceutical Co., Ltd. has set foot in the functional beverage market. Its controlled subsidiary, NCPC Hebei Huawei Health Industry Co., Ltd., launched a new product called "Xiongniu Vitamin Energy Drink". Focusing on the customers' needs like "mental refreshment, anti-fatigue, and health", this energy drink has been marketed.

News on several projects has been reported, including: Zhejiang Shengda Bio-pharm Co., Ltd.'s "production plant relocation project"; Jiangxi Tianxin Pharmaceutical Co., Ltd.'s "renovation project of vitamin H production line (by introducing intelligent technologies)"; Shangyu Jingxin Pharmaceutical Co., Ltd.'s 60 t/a vitamin D3 project; Xiamen Kingdomway Vitamin Co., Ltd.'s "vitamin A derivatives and lipoic acid series products project"; Yunnan Zewei Pharmaceutical Co., Ltd.'s "construction project of steroid hormone active pharmaceutical ingredients (APIs)".

The USD/RMB exchange rate in this Report is USD1.00=RMB7.0992 on 10 Oct., 2022, sourced from the People's Bank of China. All the prices mentioned in this Report will include the VAT, unless otherwise specified.